Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094118 | 0.85 | MEN1 (0.73) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL31661903 | 0.85 | MEN1 (0.73) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL28644956 | 0.84 | KMT2A (1.00) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL9209937 | 0.84 | KMT2A (0.72) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL9568492 | 0.84 | KMT2A (0.72) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL8228775 | 0.84 | POLB (0.91) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL29118864 | 0.84 | KEAP1 (0.65) | KMT2AMEN1HTTALDH1A1CYP1A2 | |
| SCHEMBL30676966 | 0.84 | KEAP1 (0.65) | KMT2AMEN1HTTALDH1A1CYP1A2 | |
| SCHEMBL7079531 | 0.83 | GAA (0.69) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL11882067 | 0.81 | KMT2A (0.61) | KMT2AMEN1HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-102448940-B | For the medical composition of glaucomatous treatment or prevention | UBE INDUSTRIES, LTD. (JP) | 2015-10-21 | — | — | CN | disclosed |
| CN-103965099-A | Pyridylaminoacetic Acid Compound | UBE INDUSTRIES | 2014-08-06 | — | — | CN | disclosed |
| CN-101970410-B | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2014-06-25 | — | — | CN | disclosed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | disclosed |
| US-8110338-B2 | Heat-sensitive positive-working lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-02-07 | — | — | US | disclosed |
| US-8110338-B2 | Heat-sensitive positive-working lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-02-07 | — | — | US | disclosed |
| CN-101970410-A | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2011-02-09 | — | — | CN | disclosed |
| US-20090170028-A1 | HEAT-SENSITIVE POSITIVE-WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170028-A1 | HEAT-SENSITIVE POSITIVE-WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2009-07-02 | — | — | US | disclosed |
| WO-2007099047-A1 | A HEAT-SENSITIVE POSITIVE-WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | KMT2A 578/4885MEN1 2558/4885HTT 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.